hVIVO. 

As of June 28, 2019, Venn Life Sciences Holdings Plc was acquired by Open Orphan Designated Activity Company, in a reverse merger transaction. Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.